Abiraterone Acetate Plus Prednisone Beneficial for Some With AR-positive, Triple-negative Breast Cancer

Share this content:
Treatment with abiraterone acetate plus prednisone was beneficial for some patients with molecular apocrine breast cancer,
Treatment with abiraterone acetate plus prednisone was beneficial for some patients with molecular apocrine breast cancer,

Treatment with abiraterone acetate plus prednisone was beneficial for some patients with molecular apocrine breast cancer, a subtype that expresses androgen receptor (AR), but not estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2, a study published in the Annals of Oncology has shown.1 

In this phase 2 trial, investigators assessed the efficacy and safety of abiraterone acetate plus prednisone in women with AR-positive, triple-negative metastatic or inoperable locally advanced breast cancer.

 

A total of 146 patients were included, and 138 had enough available tissue for analysis. Of those, 53 (37.6%) had AR-positive triple-negative disease and 34 were included in the study from July 2013 to December 2014. Any number of previous treatments was allowed. Abiraterone acetate (1000 mg) was administered once daily with prednisone (5 mg) twice daily until disease progression or intolerance.

The primary endpoint was clinical benefit rate at 6 months, defined as patients having a complete response, partial response, or stable disease within 6 months. Secondary endpoints included objective response rate, progression-free survival, and safety.

Results showed that out of the 30 patients eligible for evaluation of the primary endpoint, 6-month clinical benefit rate was 20.0% (95% CI, 7.7 – 38.6). One patient had a complete response, and 5 patients had stable disease within 6 months. Five patients were still being treated at the time of analysis.

Overall response rate was 6.7% (95% CI, 0.8 – 22.1) and median progression-free survival was 2.8 months (95% CI, 1.7 – 5.4).

RELATED: Concern About Breast Cancer Genetic Risk Drives Bilateral Mastectomy Decisions

In regard to safety, the most common drug-related adverse events were fatigue, hypertension, hypokalemia, and nausea; most were grade 1/2 in severity.

Reference

  1. Bonnefoi H, Grellety T, Tredan O, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) [published online ahead of print February 18, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw067.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters